Novartis and Human Genome Sciences have discontinued further development of albinterferon alfa-2b for the treatment of adults with chronic hepatitis C following feedback from U.S and EU regulatory authorities, as well as data from a Phase II study. Novartis also stopped development of Mycograb (efungumab), an antifungal agent being studied as an add-on therapy to treat invasive candidiasis in adults. As a result of these decisions, the company will record intangible asset impairment and other...